C07K 14/70507
Cd2
Official title: {cd2}
C07K14/70507 (Cd2) appears on 66 US grants and 106 published applications in this corpus.
Search patents in C07K- Granted patents
- 66
- Published applications
- 106
- Assignees
- 83
- Inventors
- 245
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 3 |
| 2003 | 0 | 5 |
| 2004 | 1 | 1 |
| 2005 | 1 | 2 |
| 2006 | 2 | 3 |
| 2007 | 1 | 1 |
| 2008 | 1 | 0 |
| 2009 | 0 | 4 |
| 2010 | 1 | 2 |
| 2011 | 1 | 1 |
| 2012 | 2 | 1 |
| 2013 | 2 | 1 |
| 2014 | 0 | 2 |
| 2015 | 3 | 0 |
| 2016 | 0 | 3 |
| 2017 | 1 | 2 |
| 2018 | 0 | 4 |
| 2019 | 2 | 4 |
| 2020 | 3 | 6 |
| 2021 | 2 | 16 |
| 2022 | 3 | 8 |
| 2023 | 4 | 11 |
| 2024 | 4 | 14 |
| 2025 | 8 | 8 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy12 May 2026US 12,624,081 B2The Trustees of the University of Pennsylvania
- Glypican-2-binding moieties, chimeric antigen receptors and uses thereof21 Apr 2026US 12,606,635 B2Nanjing Legend Biotech Co., Ltd.
- Fratricide resistant modified immune cells and methods of using the same17 Mar 2026US 12,576,151 B2Beam Therapeutics Inc.
- Engineered expression of cell surface and secreted sialidase by CAR T cells for increased efficacy in solid tumors24 Feb 2026US 12,559,719 B2The Trustees of the Unviersity of Pennsylvania
- Leucine zipper-based compositions and methods of use30 Dec 2025US 12,509,498 B2Memorial Sloan Kettering Cancer Center
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
- Chimeric Receptors to STEAP1 and Methods Of Use Thereof2 Jul 2026US 2026/0184816 A1Amgen Inc.
- Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor4 Jun 2026US 2026/0151458 A1NeoImmuneTech, Inc.
- SARS-CoV-2 Vaccine Constructs13 Nov 2025US 2025/0345415 A1Rutgers, The State University of New Jersey
Most cited
By later US patents
- Chimeric receptor molecules for delivery of co-stimulatory signals260US 5,686,281 ACell Genesys, Inc. · 1997
- Chimeric receptor molecules for delivery of co-stimulatory signals162US 5,712,149 ACell Genesys, Inc. · 1998
- Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction67US 6,162,432 ABiogen, Inc. · 2000
- Regulation of systemic immune responses utilizing cytokines and antigens59US 5,904,920 AThe Johns Hopkins University School of Medicine · 1999
- Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells45US 6,083,751 ATargeted Genetics Corporation · 2000